.jpg?crop=true&keep=c&q=80&color=ffffffff&u=8anjqk&w=1600&h=500)
Industry Focus
|
Regina Kelder, Mary Parker
Introducing The Eureka Index: The Drug Development Landscape
Ten statistics that shed light on biomedical research over the years
Data drives science. It delivers bad news, good news, and, perhaps most importantly, conveys important trends and outcomes that laboratories and government agencies need to know. The Eureka Index is a new feature launched this month by Charles River’s scientific blog. It captures just a few of the stats we think are particularly interesting and revealing. Today’s Index takes an overall look at different aspects of the drug development landscape, but future indexes will examine specific topics, such as trends in New Approach Methodologies, science education, public health, computers in drug development, and green Pharma.
Number of novel drugs approved by the US Food and Drug Administration in 2005: 20
Number of Novel Drugs approved by the US Food and Drug Administration in 2025: 46
Percent of novel drugs approved by the US Food and Drug Administration in 2019 that Charles River worked on: 85%
Percent of novel drugs approved by the US Food and Drug Administration in 2025 that Charles River worked on: Over 90%
The number of novel antibody therapies approved in the US and China in 2010: 3 and 0
The number of novel antibody therapies approved in the US and China in 2015: 6 and 0
The number of novel antibody therapies approved in the US and China in 2025: 9 and 18
Number of AI-discovered molecules in clinical trials in 2015 compared to 2023: 1 vs. 67
Number of rare diseases being targeted by pharmaceutical companies in 2013: 389
Number of rare diseases being targeted by pharmaceutical companies in 2026: 792
*Subscriber-based content